ClearNote Health Secures $52M to Expand Early Cancer Detection
June 1, 2026, 4:20 pm
National Cancer Institute (NCI)
Location: United States, Maryland, Bethesda
Employees: 1001-5000
Founded date: 1937
ClearNote Health secured $52 million in Series D funding. This capital fuels accelerated growth in early cancer detection. The round elevates total funding to $185 million. New President and COO Kevin Keegan joins the leadership. ClearNote Health advances its noninvasive epigenomic tests. These tools target deadly cancers like pancreatic and ovarian. The company drives commercial expansion and clinical studies. It empowers earlier diagnosis for high-risk patients. This move strengthens the fight against cancer.
ClearNote Health just announced a significant financial milestone. The company closed a $52 million Series D funding round. This latest injection brings its total capital raised to over $185 million. The funding propels ClearNote Health's mission. It aims to revolutionize early cancer detection. The company focuses on noninvasive, accurate testing. Its technology identifies cancers at their most treatable stages. This is a critical step in oncology innovation.
The Series D round drew considerable investor interest. Founding investor Mattias Westman led the financing. A global, large, long-only active manager also participated. High-profile investors joined the effort. Former Citigroup CEO Sandy Weill contributed. ClearNote Health co-founder Dr. Stephen Quake also invested. A prominent Seattle-based family office participated. Other institutional investors from the U.S. and abroad rounded out the group. This diverse backing underscores confidence. It highlights belief in ClearNote Health's platform and potential.
Capital from this round serves multiple strategic objectives. ClearNote Health plans extensive commercial expansion. It will scale operational capabilities. The company will execute vital clinical studies. Product development also receives significant investment. These funds ensure broader access. They deliver Avantect early cancer detection tests to more patients. The Virtuoso epigenomic drug development platform also benefits. This investment accelerates market penetration. It strengthens the company’s scientific foundation.
A key leadership appointment coincides with the funding news. Kevin Keegan steps in as President and Chief Operating Officer. Keegan brings nearly three decades of experience. His background spans the clinical diagnostics industry. He held senior roles at major companies. These include BD, Illumina, and Hologic. At Illumina, he served as general manager of oncology. He notably launched a widely adopted tumor profiling test. Keegan’s expertise in molecular diagnostics is invaluable. His operational and commercial leadership will drive growth. He will help scale the organization globally. He expands access to early cancer detection tests.
ClearNote Health’s core innovation lies in its Virtuoso epigenomics platform. Scientists at Stanford University originally developed this technology. Dr. Stephen Quake's laboratory pioneered its creation. The platform combines cutting-edge artificial intelligence. It integrates advanced bioinformatics. This powerful combination measures active biological differences. It detects these subtle changes between cancer and healthy cells. All this occurs within a simple blood sample. This noninvasive approach offers immense patient benefits.
The company’s flagship products are the Avantect tests. These blood-based tests target specific, deadly cancers. The Avantect Pancreatic Cancer Test identifies pancreatic cancer early. The Avantect Ovarian Cancer Test focuses on ovarian cancer. Both diseases are notoriously difficult to detect. Conventional methods often miss early indicators. ClearNote Health’s sensitive tests offer a solution. They aim to identify cancers in high-risk patient populations sooner. Early detection greatly improves treatment outcomes. Patients benefit when treatment begins at an earlier stage.
ClearNote Health’s progress extends beyond specific tests. Its multi-cancer detection test garners national attention. The National Cancer Institute (NCI) selected it. It is one of only two blood-based technologies chosen. The NCI’s Vanguard Study will evaluate it. This selection validates the technology’s promise. It positions ClearNote Health at the forefront. The company leads multi-cancer screening research. Such recognition underscores scientific rigor. It highlights the platform's potential impact.
CEO Dave Mullarkey leads the company's strategic vision. He oversees the integration of advanced science. He guides its application in real-world diagnostics. The goal is clear: save lives through earlier intervention. The company's momentum builds steadily. It enhances the Avantect Pancreatic Cancer Test. This platform utilizes multiomic analysis. It incorporates machine learning algorithms. These features improve detection sensitivity. They also boost specificity. This continuous improvement ensures accuracy. It maintains reliability in critical diagnostic tools.
The clinical diagnostics industry is evolving rapidly. Demand for noninvasive early cancer detection tools surges. ClearNote Health positions itself strategically. It meets this growing need. Its technology provides actionable insights. It empowers clinicians. It offers hope to patients at elevated risk. This funding round strengthens its market position. It secures resources for expansion. It allows continued innovation. The company's impact on public health will be substantial.
ClearNote Health's approach marks a paradigm shift. It moves from symptomatic diagnosis to proactive screening. This transition can transform cancer care. It offers the promise of a future. A future where more cancers are found early. A future where more lives are saved. The company’s focus on epigenomics is key. This field explores changes in gene expression. It does not alter the underlying DNA sequence. These epigenetic signals are powerful biomarkers. They offer unique insights into cancer biology. ClearNote Health harnesses this power. It translates complex science into practical tests.
The appointment of Kevin Keegan is pivotal. His experience in launching diagnostic tools is critical. He understands market dynamics. He knows operational scale. These are essential for a growing company. His leadership ensures efficient expansion. It supports global accessibility. The integration of his expertise with ClearNote Health's innovation creates synergy. This synergy drives the company forward. It accelerates its impact on patient care.
ClearNote Health continues to build on its foundation. Its proprietary platform offers significant advantages. Noninvasive blood tests simplify screening. They reduce patient burden. They make testing more accessible. This is especially true for high-risk populations. Early detection leads to less aggressive treatments. It offers higher chances of cure. The company’s commitment remains firm. It seeks to improve outcomes for all. This latest funding round solidifies that commitment. It empowers the next phase of growth. The future of early cancer detection looks brighter. ClearNote Health leads this charge.
ClearNote Health just announced a significant financial milestone. The company closed a $52 million Series D funding round. This latest injection brings its total capital raised to over $185 million. The funding propels ClearNote Health's mission. It aims to revolutionize early cancer detection. The company focuses on noninvasive, accurate testing. Its technology identifies cancers at their most treatable stages. This is a critical step in oncology innovation.
The Series D round drew considerable investor interest. Founding investor Mattias Westman led the financing. A global, large, long-only active manager also participated. High-profile investors joined the effort. Former Citigroup CEO Sandy Weill contributed. ClearNote Health co-founder Dr. Stephen Quake also invested. A prominent Seattle-based family office participated. Other institutional investors from the U.S. and abroad rounded out the group. This diverse backing underscores confidence. It highlights belief in ClearNote Health's platform and potential.
Capital from this round serves multiple strategic objectives. ClearNote Health plans extensive commercial expansion. It will scale operational capabilities. The company will execute vital clinical studies. Product development also receives significant investment. These funds ensure broader access. They deliver Avantect early cancer detection tests to more patients. The Virtuoso epigenomic drug development platform also benefits. This investment accelerates market penetration. It strengthens the company’s scientific foundation.
A key leadership appointment coincides with the funding news. Kevin Keegan steps in as President and Chief Operating Officer. Keegan brings nearly three decades of experience. His background spans the clinical diagnostics industry. He held senior roles at major companies. These include BD, Illumina, and Hologic. At Illumina, he served as general manager of oncology. He notably launched a widely adopted tumor profiling test. Keegan’s expertise in molecular diagnostics is invaluable. His operational and commercial leadership will drive growth. He will help scale the organization globally. He expands access to early cancer detection tests.
ClearNote Health’s core innovation lies in its Virtuoso epigenomics platform. Scientists at Stanford University originally developed this technology. Dr. Stephen Quake's laboratory pioneered its creation. The platform combines cutting-edge artificial intelligence. It integrates advanced bioinformatics. This powerful combination measures active biological differences. It detects these subtle changes between cancer and healthy cells. All this occurs within a simple blood sample. This noninvasive approach offers immense patient benefits.
The company’s flagship products are the Avantect tests. These blood-based tests target specific, deadly cancers. The Avantect Pancreatic Cancer Test identifies pancreatic cancer early. The Avantect Ovarian Cancer Test focuses on ovarian cancer. Both diseases are notoriously difficult to detect. Conventional methods often miss early indicators. ClearNote Health’s sensitive tests offer a solution. They aim to identify cancers in high-risk patient populations sooner. Early detection greatly improves treatment outcomes. Patients benefit when treatment begins at an earlier stage.
ClearNote Health’s progress extends beyond specific tests. Its multi-cancer detection test garners national attention. The National Cancer Institute (NCI) selected it. It is one of only two blood-based technologies chosen. The NCI’s Vanguard Study will evaluate it. This selection validates the technology’s promise. It positions ClearNote Health at the forefront. The company leads multi-cancer screening research. Such recognition underscores scientific rigor. It highlights the platform's potential impact.
CEO Dave Mullarkey leads the company's strategic vision. He oversees the integration of advanced science. He guides its application in real-world diagnostics. The goal is clear: save lives through earlier intervention. The company's momentum builds steadily. It enhances the Avantect Pancreatic Cancer Test. This platform utilizes multiomic analysis. It incorporates machine learning algorithms. These features improve detection sensitivity. They also boost specificity. This continuous improvement ensures accuracy. It maintains reliability in critical diagnostic tools.
The clinical diagnostics industry is evolving rapidly. Demand for noninvasive early cancer detection tools surges. ClearNote Health positions itself strategically. It meets this growing need. Its technology provides actionable insights. It empowers clinicians. It offers hope to patients at elevated risk. This funding round strengthens its market position. It secures resources for expansion. It allows continued innovation. The company's impact on public health will be substantial.
ClearNote Health's approach marks a paradigm shift. It moves from symptomatic diagnosis to proactive screening. This transition can transform cancer care. It offers the promise of a future. A future where more cancers are found early. A future where more lives are saved. The company’s focus on epigenomics is key. This field explores changes in gene expression. It does not alter the underlying DNA sequence. These epigenetic signals are powerful biomarkers. They offer unique insights into cancer biology. ClearNote Health harnesses this power. It translates complex science into practical tests.
The appointment of Kevin Keegan is pivotal. His experience in launching diagnostic tools is critical. He understands market dynamics. He knows operational scale. These are essential for a growing company. His leadership ensures efficient expansion. It supports global accessibility. The integration of his expertise with ClearNote Health's innovation creates synergy. This synergy drives the company forward. It accelerates its impact on patient care.
ClearNote Health continues to build on its foundation. Its proprietary platform offers significant advantages. Noninvasive blood tests simplify screening. They reduce patient burden. They make testing more accessible. This is especially true for high-risk populations. Early detection leads to less aggressive treatments. It offers higher chances of cure. The company’s commitment remains firm. It seeks to improve outcomes for all. This latest funding round solidifies that commitment. It empowers the next phase of growth. The future of early cancer detection looks brighter. ClearNote Health leads this charge.